• Radionuclide Tx Wins in Third-Line Metastatic CRPC

    One year ago - By MedPageToday

    Prostate-specific membrane antigen -targeted radionuclide therapy reduced the risk of disease progression or death versus cabazitaxel in men with previously treated metastatic castration-resistant prostate cancer...
    Read more ...

     

  • The headlines of Master Doctor